The economic value of a quadrivalent versus trivalent influenza vaccine

Bruce Y. Lee, Sarah M. Bartsch, Alyssa M. Willig

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.

Original languageEnglish (US)
Pages (from-to)7443-7446
Number of pages4
Issue number52
StatePublished - Dec 14 2012
Externally publishedYes


  • Economics
  • Influenza
  • Quadrivalent vaccine
  • Trivalent vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'The economic value of a quadrivalent versus trivalent influenza vaccine'. Together they form a unique fingerprint.

Cite this